The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .
Phosphatidylinositol-3-kinase (PI3K) is an important target in cancer due to the deregulation of the PI3K/ Akt signaling pathway in a wide variety of tumors. A series of thieno[3,2-d]pyrimidine derivatives were prepared and evaluated as inhibitors of PI3 kinase p110alpha. The synthesis, biological activity, and further profiling of these compounds are described. This work resulted in the discovery of 17, GDC-0941, which is a potent, selective, orally bioavailable inhibitor of PI3K and is currently being evaluated in human clinical trials for the treatment of cancer.
Folkes
Adrian J
AJ
Piramed Pharma, 957 Buckingham Avenue, Slough, Berks SL1 4NL, United Kingdom. adrian.folkes@piramed.com
Ahmadi
Khatereh
K
Alderton
Wendy K
WK
Alix
Sonia
S
Baker
Stewart J
SJ
Box
Gary
G
Chuckowree
Irina S
IS
Clarke
Paul A
PA
Depledge
Paul
P
Eccles
Suzanne A
SA
Friedman
Lori S
LS
Hayes
Angela
A
Hancox
Timothy C
TC
Kugendradas
Arumugam
A
Lensun
Letitia
L
Moore
Pauline
P
Olivero
Alan G
AG
Pang
Jodie
J
Patel
Sonal
S
Pergl-Wilson
Giles H
GH
Raynaud
Florence I
FI
Robson
Anthony
A
Saghir
Nahid
N
Salphati
Laurent
L
Sohal
Sukhjit
S
Ultsch
Mark H
MH
Valenti
Melanie
M
Wallweber
Heidi J A
HJ
Wan
Nan Chi
NC
Wiesmann
Christian
C
Workman
Paul
P
Zhyvoloup
Alexander
A
Zvelebil
Marketa J
MJ
Shuttleworth
Stephen J
SJ